54.87
0.49 (0.90%)
| Penutupan Terdahulu | 54.38 |
| Buka | 54.83 |
| Jumlah Dagangan | 1,946,902 |
| Purata Dagangan (3B) | 2,808,193 |
| Modal Pasaran | 10,350,566,400 |
| Harga / Pendapatan (P/E Ke hadapan) | 2.50 |
| Harga / Jualan (P/S) | 3.04 |
| Harga / Buku (P/B) | 3.52 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 29 Jul 2025 - 4 Aug 2025 |
| Margin Keuntungan | -37.29% |
| Margin Operasi (TTM) | -4.92% |
| EPS Cair (TTM) | -5.59 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 10.30% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 115.55% |
| Nisbah Semasa (MRQ) | 2.15 |
| Aliran Tunai Operasi (OCF TTM) | 210.54 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | 61.42 M |
| Pulangan Atas Aset (ROA TTM) | -1.87% |
| Pulangan Atas Ekuiti (ROE TTM) | -37.09% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Menurun | Menurun |
| Diagnostics & Research (Global) | Menurun | Menurun | |
| Stok | Exact Sciences Corporation | Menurun | Menurun |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -2.0 |
| Purata Bergerak Teknikal | -5.0 |
| Osilator Teknikal | 0.5 |
| Purata | -1.75 |
|
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact’s Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 1.07% |
| % Dimiliki oleh Institusi | 100.35% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 75.00 (Barclays, 36.69%) | Beli |
| Median | 63.00 (14.82%) | |
| Rendah | 54.00 (RBC Capital, -1.59%) | Pegang |
| Purata | 64.50 (17.55%) | |
| Jumlah | 5 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 49.07 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Baird | 02 May 2025 | 72.00 (31.22%) | Beli | 51.55 |
| Barclays | 02 May 2025 | 75.00 (36.69%) | Beli | 51.55 |
| 10 Apr 2025 | 55.00 (0.24%) | Beli | 43.74 | |
| Evercore ISI Group | 02 May 2025 | 66.00 (20.28%) | Beli | 51.55 |
| RBC Capital | 02 May 2025 | 54.00 (-1.59%) | Pegang | 51.55 |
| Guggenheim | 11 Apr 2025 | 60.00 (9.35%) | Beli | 44.45 |
| Mizuho | 10 Apr 2025 | 60.00 (9.35%) | Beli | 43.74 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |